In This Article:
CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.11% for the day. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 1.89%.
Shares of the company have depreciated by 14.87% over the course of the past month, underperforming the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$1.20, marking a 209.09% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.83 million, indicating a 94.62% decrease compared to the same quarter of the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.75% higher. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 66, positioning it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report